Category Archives: Physiology

Sensors were allowed to prove themselves by test with increased pre-night temperature in tomato – hortidaily.com

In 'The Road to Digital Green Fingers' project, researchers increased the pre-night temperature in a tomato cultivation by one degree for four weeks. In this way, the crop was 'bullied' to see how far it could go, but especially also to understand the physiology behind the measurements. The better that goes, the easier it will be to cultivate remotely later on.

"The crop is now recovering," said Alex van Klink of the Delphy Improvement Center, responsible for the research for the project, about the treatment that was stopped in week 24. He saw that the crop started to consume assimilates faster. "In itself we can explain from the physiology what the raising of the pre-night temperature does, but the question for us is mainly whether you can also catch it with sensors and then also can understand it."

Alex in the test greenhouse

Understanding measurementsIn the latter, the researchers from Delphy and Wageningen University & Research are interested in and various other parties as well, namely AgroEnergy, 2Grow, De Ruiter Seeds, Hazera Seeds, Signify and Ludvig Svensson. All parties are primarily concerned in understanding plant reactions with the sensor network. In this way, plant responses can be measured before they are visible to the naked eye. Ultimately, this should lead to the application of the knowledge in order to start controlling the cultivation.

More objective measuringUsing a combination of, among other things, sap flow sensors and scales to measure the weight of the plant, the researchers are mapping balance or imbalance in water consumption, assimilates, but also in growth height and fruits.

"By using sensors for more objective measuring in the near future, you can see things that the grower or advisor cannot see with the naked eye. That means that the grower can soon be less in the greenhouse and also that you can limit the movements of advisers from greenhouse to greenhouse. An advantage with the high virus pressure that is present in, for example, tomatoes."

Six treatments testedIn total, six treatments will be tested in the project, which runs until mid-September and for which financial support was obtained from the Topsector Tuinbouw & Uitgangsmaterialen. "With EC, lighting and irrigation, well also be looking for the limit again. And in case we would cross it, that will also be instructive. We have that advantage over production growers."

A follow-up test can then be carried out with the acquired knowledge. In this way, greenhouse horticulture is progressing step by step towards autonomous cultivation, but not without people that will be able to keep in step with the technology and also will be able to fully rely on it. The latter is an important condition for the grower with green fingers in order to relinquish control.

For more information:Delphywww.delphy.nl

Alex van Klinka.vanklink@delphy.nl

More:
Sensors were allowed to prove themselves by test with increased pre-night temperature in tomato - hortidaily.com

Trial to see if immune booster can protect cancer patients from Covid-19 – ThePrint

Text Size:A- A+

New Delhi: As the coronavirus pandemic continues to rage through the world, scientists are making new revelations about the virus every day.

Here are some of the latest research developments on the Covid-19 front.

Scientists in Canada have launched clinical trials focussed on strengthening the immune system for cancer patients one of the most vulnerable populations to protect them from Covid-19.

The trial involves IMM-101, an inactivated bacteria that broadly stimulates the innateimmune system, which is the first to kick in when the body encounters a novel pathogen.

The researchers hope that boosting cancer patients immune systems with IMM-101 will protect them from developing severe Covid-19 and other dangerous lung infections.

The researchers said that an effective vaccine providing specific protection against Covid-19 could take another year or more to develop. Meanwhile, they believe the IMM-101 may be able to protect cancer patients from developing a serious Covid infection.

Also read: Asthma does not increase risk or severity of Covid-19, says new study

We are deeply grateful to our readers & viewers for their time, trust and subscriptions.

Quality journalism is expensive and needs readers to pay for it. Your support will define our work and ThePrints future.

SUBSCRIBE NOW

A review of Covid-19 patients has shown that cases of brain complications linked to the coronavirus infection, such as confusion, stroke and inflammation of the brain, are occurring across the globe.

Published in The Lancet Neurology, the study has found that strokes, delirium and other neurological complications have been reported from most countries with large outbreaks of the disease.

The infection caused by the novel coronavirus has been mostly associated with problems such as difficulty in breathing, fever and cough. However, it is now becoming clear that other problems can also occur in patients.

For this study, researchers analysed findings from Covid-19 studies across the globe that reported on neurological complications. The review included studies from China, Italy and the US. It found nearly 1,000 patients with Covid-19-associated brain, spinal cord and nerve diseases.

While these complications are uncommon, the large number of Covid-19 cases globally means the overall number of patients with neurological problems is also likely to be high.

Naturally occurring molecules called resolvins can be harnessed to control the life-threatening immune reaction, called a cytokine storm, in Covid-19 patients, scientists have said.

A cytokine storm is when the bodys immune system overreacts and begins attacking healthy cells too.

The cytokine storm in Covid-19 patients can lead to respiratory failure, organ damage and potential death.

In a study published in the Cancer and Metastasis Reviews, researchers have said that controlling the local and systemic inflammatory response in Covid-19 may be as important as anti-viral therapies.

They suggest that a family of molecules naturally produced by the human body may be harnessed to resolve inflammation in patients with severe Covid-19. This would reduce the acute respiratory distress and other life-threatening complications associated with the viral infection.

Resolvins can actively turn off inflammation. Researchers have previously demonstrated that resolvins and related molecules can play a role in preventing cancer metastasis and progression.

These are current clinical trials on these molecules, to look at their use against other inflammatory diseases. Scientists have suggested that they could be re-deployed for the management of Covid-19.

Scientists have identified the differences in lung physiology and immune function in children that could explain why they are less susceptible to severe Covid-19 illness than adults.

Published in the American Journal of Physiology-Lung Cellular and Molecular Physiology, the study suggests that children naturally have less ACE2 in the lungs than adults. Angiotensin-converting enzyme 2s, called ACE2, allow SARS-CoV-2 to enter the bodys cells.

According to the study, only about 1.7 per cent of the first 1,49,082 cases in the US were under 18 years of age.

The findings from the study require further examination, and may hold the key to identifying therapeutic agents, researchers have said.

Months of self-isolation and social distancing can trigger stressors in the body that increase vulnerability to upper respiratory viruses and perhaps coronavirus, a study has suggested.

To slow the spread of coronavirus, many communities issued stay-at-home measures, increasing interpersonal stressors like loneliness, loss of employment and familial conflict.

According to an article published in the Perspectives on Psychological Science, these stressors may be powerful predictors of how a person will respond if exposed to coronavirus.

In a series of studies, researchers found that participants experiencing interpersonal stressors had a greater chance of developing upper respiratory illnesses when exposed to cold viruses.

Interpersonal stressors might play a similar role in response to the coronavirus, increasing a persons vulnerability to Covid-19.

The study indicates that social support may offer a protective shield against respiratory infection and illness.

Also read: CanSino, Moderna, Novavax: A list of Covid vaccines under clinical trials across the world

Subscribe to our channels on YouTube & Telegram

News media is in a crisis & only you can fix it

You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.

You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the medias economics is broken. But a big one is that good people are not yet paying enough for good journalism.

We have a newsroom filled with talented young reporters. We also have the countrys most robust editing and fact-checking team, finest news photographers and video professionals. We are building Indias most ambitious and energetic news platform. And we arent even three yet.

At ThePrint, we invest in quality journalists. We pay them fairly and on time even in this difficult period. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is. Our stellar coronavirus coverage is a good example. You can check some of it here.

This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it. Because the advertising market is broken too.

If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous, and questioning journalism, please click on the link below. Your support will define our journalism, and ThePrints future. It will take just a few seconds of your time.

Support Our Journalism

Visit link:
Trial to see if immune booster can protect cancer patients from Covid-19 - ThePrint

Jeremy Xu Joins Ingredion as Senior Vice President and Chief Innovation Officer – GlobeNewswire

WESTCHESTER, Ill., July 09, 2020 (GLOBE NEWSWIRE) -- Ingredion Incorporated (NYSE: INGR), a leading global provider of ingredient solutions, today announced that Jeremy Xu has been named senior vice president, and chief innovation officer, effective October 1. In this capacity, Xu will be responsible for advancing the Companys focus on specialty growth platforms, identifying new growth opportunities and overseeing the Ingredion Idea Labs innovation centers. Xu will report to Jim Zallie, president and chief executive officer.Xuwill succeed Tony DeLio who will be retiring in February 2021 after 14 years of service.

Xu joins the Company from Royal DSM, where he spent four years leading a global business unit in the nutritional ingredients space. Before that role, he spent 16 years at DuPont serving in a variety of leadership roles across Asia and the U.S.

Jeremy is an accomplished global leader with a strong reputation for successfully driving innovation and growth while cultivating high-performing, agile teams, said Zallie. Jeremy brings a global perspective and deep specialty food ingredient experience, which is critical as we identify new opportunities for our customers. We look forward to having an executive of his caliber join the Ingredion team.

Xu holds a bachelors degree in biology and biomedical engineering from Zhejiang University in China and earned a doctorate in biochemistry and molecular biology as well as a masters degree in business administration from Purdue University. He also holds a masters degree in plant physiology from the Chinese University of Hong Kong. Xu is fluent in English, Mandarin and Cantonese. Xu will relocate to the New Jersey area from Switzerland with his family.

ABOUT THE COMPANY

Ingredion Incorporated (NYSE: INGR) headquartered in the suburbs of Chicago, is a leading global ingredient solutions provider serving customers in more than 120 countries. With 2019 annual net sales of more than $6 billion, the company turns grains, fruits, vegetables and other plant-based materials into value-added ingredient solutions for the food, beverage, animal nutrition, brewing and industrial markets. With Ingredion Idea Labsinnovation centers located around the world and more than 11,000 employees, the Company co-creates with customers and fulfills its purpose of bringing the potential of people, nature and technology together to make life better. Visitingredion.comfor more information and the latest Company news.

CONTACTS:Investors: Tiffany Willis, 708-551-2592Media: Becca Hary, 708-551-2602

See more here:
Jeremy Xu Joins Ingredion as Senior Vice President and Chief Innovation Officer - GlobeNewswire

With careful adoption, soy and wheat can help maintain seniors’ muscles, says expert – Clinical Daily News – McKnight’s Long Term Care News

News > Clinical Daily News

Plant protein can help older adults maintain muscle mass, but users must adjust for any loss of animal protein when making dietary changes, say researchers.

In a new study, plant-based proteins helped to maintain the size and quality of aging muscles, wrote investigators from Kings College London. But animal proteins were more effective at helping to form muscle. A larger dose of plant protein is therefore necessary to achieve the same muscle-building response, they concluded.

Simply transitioning from an animal-based protein diet to a plant-based diet, without adjusting total protein intake, will likely be detrimental to muscle health during aging, said Professor Oliver Witard, an expert in exercise metabolism and nutrition. A more balanced and less extreme approach to changing dietary behavior, meaning eating both animal and plant-based proteins, is best, he concluded.

Plant-based diets have numerous health benefits and are becoming more popular. In fact, 39% of Americans responded that they are actively trying to eat more plant-based foods, according to a 2017 Nielsen Homescan survey.

The research was presented this week at The Physiological Societys virtual early career conference Future Physiology 2020.

Please login or register first to view this content.

LoginRegister

Next post in Clinical Daily NewsClose

Read more here:
With careful adoption, soy and wheat can help maintain seniors' muscles, says expert - Clinical Daily News - McKnight's Long Term Care News

Fluence Leads Global Research Initiative to Study Impact of Light Quality on Plant Development, Yield and Crop Quality – Financial Post

The ongoing multi-country and multi-crop initiative advances Fluences and the greater horticultural industrys understanding of the interaction between light and life

AUSTIN, Texas Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and agriculture production, has expanded its global photobiology research program, which encompasses studies on multiple vine crops, leafy greens and medical cannabis in the United States, Canada, Germany, Belgium and the Netherlands.

Tapping into a global network of trusted research institutions

Fluence leverages a network of leading research institutions and partners for its program, including Wageningen University & Research (WUR) for tomatoes; Proefstation voor de Groenteteelt (Proefstation) to study cucumbers; Harrow Research and Development Centre for peppers; The Technical University of Munichs Greenhouse Lab Centre for lettuce; Wageningen Plant Researchs Greenhouse Horticulture business unit and Compassionate Cultivation for medical cannabis.

The latest studies utilized Fluences VYPR Series top light and expanded PhysioSpec spectra offeringwhich features four spectra and market-leading efficacies up to 3.8 mol/Jin a randomized block design with triple replicates during a winter growing season. A leader in global horticultural research, WUR explored the impact of each spectrum on Merlice and Brioso tomato cultivars.

Traditionally, tomato plants are grown under high-pressure sodium lights, where only one spectrum is available to growers, said Ep Heuvelink, associate professor of horticulture and product physiology at WUR. Given the efficacy of Fluences LED solutions and the companys spectra options, its critical to understand how various tomato cultivars perform under LEDs and diversified spectra.

Featuring a 1.3-hectare greenhouse with 38 independent compartments, Proefstations facility brings more than 50 years of experience in research on the cultivation of greenhouse and field vegetables.

Light spectra have an important impact on plant and fruit quality, and weve found that LEDs provide a more optimal, precise spectrum than HPS, said Jonas De Win, lead cucumber researcher at Proefstation. This research is critical for our growers who frequently ask which spectra is best for their greenhouse and crop variety. Our goal is to act as the bridge between cucumber growers and the latest scientific research, enabling cultivators to enhance their environments and ultimately become more profitable.

Crop-based research results inform unique lighting strategies

LED lighting is a proven, viable option for global crop growers, said David Cohen, CEO of Fluence. Our exploration of the impact of light quality on plant development is driving a deeper conversation about efficacy, yield and quality between growers and their partners. Our commitment to leading cross-geography, multi-crop research will help guide growers in building a supplemental lighting strategy tailored to their unique business goals.

Fluence will distribute research results throughout the year, uncovering how the optimal lighting strategy varies by crop, species and environment. Results from Fluences cucumber trial with Proefstation will be previewed on July 15, 2020 on a webinar hosted by Leo Lansbergen, Fluences horticulture service specialist and expert in cucumber cultivation.

There is no one-size-fits-all approach to determining your lighting strategy, said David Hawley, Ph.D., Fluences senior scientist. Exploring how to manipulate LED technology presents a world of opportunity for us as scientists, but ultimately benefits growers looking to customize their cultivation environments. Insights derived from each study will help growers understand how various spectra impact harvests and plant quality, including factors ranging from nutrition and flavor to shelf life.

For more information about Fluence and its ongoing research initiatives, visit http://www.fluence.science.

About Fluence by OSRAM

Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM, creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the worlds top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit http://www.fluence.science.

Link to high resolution pictures: http://www.fluence.science/press-links

View source version on businesswire.com: https://www.businesswire.com/news/home/20200708005470/en/

Contacts

Media Contact: For North America, Emma Chase emma@redfancommunications.com Phone: 512-917-4319

For EMEA, Silvia Nagyova s.nagyova@osram.com Phone: +49 (89) 6213-3939

#distro

Continued here:
Fluence Leads Global Research Initiative to Study Impact of Light Quality on Plant Development, Yield and Crop Quality - Financial Post

Cue Biopharma Announces PLOS One Publication Demonstrating the Generation and Evaluation of Novel Molecules with Directed Mutations within the B7…

- Novel insights into receptor binding events and interfaces have led to generation of selective molecules with unique biochemical and functional properties through an effort led by Dr. Steven Almo at Albert Einstein College of Medicine

- Enhances Cue Biopharmas ability to engineer molecules for therapeutic immune modulation through Immuno-STAT and Neo-STAT platforms

CAMBRIDGE, Mass., July 08, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, today announced the peer-reviewed publication of data focused on generation and evaluation of libraries of checkpoint molecules with directed mutations providing novel biological properties in a paper titled Mechanistic dissection of the PD-L1:B7-1 co-inhibitory immune complex.

In this work, researchers focused primarily on the recently described interaction between B7-1 and PD-L1, two molecules within the B7 superfamily, which are of critical importance for controlling anti-tumor immunity, autoimmunity and infectious diseases. By combining cell microarray and high-throughput FACS methods to screen binding events and map binding interfaces, selective mPD-L1 and mB7-1 mutants with distinct biochemical and functional properties were generated that altered the binding interactions between PD-1 and PD-L1, and CTLA-4 and B7-1 as well as the recently described PD-L1 and B7-1 binding interaction.

Our efforts expand upon the fundamental understanding of critical binding interactions and related downstream signaling cascades by more completely defining the molecular interactions between these key cell surface molecules, said Steven C. Almo, Ph.D., professor and chair of biochemistry, professor of physiology & biophysics and the Wollowick Family Foundation chair in multiple sclerosis and immunology at Albert Einstein College of Medicine, and co-founder of Cue Biopharma. Through these studies we are able to decipher specific molecular and atomic insights to engineer and generate molecules with unique biochemical and functional properties with the aim of developing more efficacious treatments with fewer unwanted side effects.

This approach augments and supplements Cue Biopharmas Immuno-STAT and Neo-STAT platforms, leveraging rational protein engineering to generate therapeutic frameworks possessing desirable drug properties while attenuating and/or abrogating unwanted, deleterious effects. CUE-101, Cue Biopharmas lead asset from the IL-2 based CUE-100 Series, was rationally engineered to enhance the selective activation of the beneficial CD8+ anti-tumor T cells, while abrogating the effects on other immune cell populations that are deleterious to cancer therapy, such as regulatory T cells. A CUE-101 Phase 1 monotherapy trial is ongoing, with enrollment of patients in dose escalation at 13 leading centers in the United States for the treatment of post first-line metastatic and recurrent HPV+ advanced head and neck cancer. Early data metrics from this trial are encouraging with demonstration of safety and tolerability, dose proportional exposure pharmacokinetics (PK) and early, albeit anecdotal, evidence of biologic activity through pharmacodynamics (PD) biomarkers and clinical benefit.

We are highly encouraged by these findings and further research being conducted in Dr. Almos laboratory, which provides us with additional, novel insights into immune receptors, said Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma. Learnings from this important work will augment and further advance our internal efforts to build out the Immuno-STAT and Neo-STAT platforms and enhance our ability to dial-in/dial-out specific molecular interactions for the therapeutic modulation of the immune system in cancer, autoimmune diseases and chronic infectious diseases.

Albert Einstein College of Medicine and its faculty members acknowledge the following relationships with Cue Biopharma, Inc.: Dr. Almo holds equity in Cue Biopharma, Inc., receives royalties from existing license agreements between Einstein and Cue,and is a member of its Science Advisory Board; Dr.Garrett-Thomson receives royalties; and Albert Einstein College of Medicine holds equity in Cue and receives royalties.

AboutCue BiopharmaCue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body to transform the treatment of cancer and autoimmune diseases. The companys proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) is designed to harness the bodys intrinsic immune system without the need for ex vivo manipulation.

Headquartered inCambridge, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.

For more information, visitwww.cuebiopharma.comand follow us on Twitter https://twitter.com/CueBiopharma.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as believe, expect, may, will, should, would, could, seek, intend, plan, goal, project, estimate, anticipate, strategy, future, likely or other comparable terms. All statements other than statements of historical facts included in this press release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding anticipated results of our drug development efforts, including study results, and our expectations regarding regulatory developments and expected future operating results. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, our limited operating history, limited cash and a history of losses; our ability to achieve profitability; potential setbacks in our research and development efforts including negative or inconclusive results from our preclinical studies, our ability to secure requiredU.S. Food and Drug Administration(FDA) or other governmental approvals for our product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including COVID-19, including possible effects on our operations and clinical trials; negative or inconclusive results from our clinical studies or serious and unexpected drug-related side effects or other safety issues experienced by participants in our clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to theFDA; our reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; our ability to obtain adequate financing to fund our business operations in the future; ; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor ContactAshley R. RobinsonLifeSci Advisorsarr@lifesciadvisors.com

Media ContactAlison ChenLifeSci Communicationsachen@lifescicomms.com

Read the original here:
Cue Biopharma Announces PLOS One Publication Demonstrating the Generation and Evaluation of Novel Molecules with Directed Mutations within the B7...

Anatomage Announces Its Upcoming eBook For Students To Experience and Interact with True-Human Cadavers Online – WFMZ Allentown

SAN JOSE, Calif., July 2, 2020 /PRNewswire/ -- Anatomage Inc, a market leader in 3D medical imaging technology, today announces Anatomage eBook - an eBook that enables students to study anatomy and physiology through interacting with the anatomy of true-human cadavers online.

Anatomage eBook consists of 25 chapters that feature major anatomy and physiology concepts of 12 major body systems and functions. For each concept, users are visually guided through all of the related body parts - from macro to microstructures - with educational texts and dynamic images. As the majority of images from Anatomage eBook stem from the Anatomage Table's true-human cadavers, the digital contents exhibit accurate human anatomy content that helps students decipher and memorize anatomical terms easier.

Anatomage eBook is optimized for online learning which allows students to access the contents from anywhere. Unlike other online tools, the eBook offers a unique user experience that is highly engaging and easy to navigate. The contents are highly visual and based on Anatomage's renowned photorealistic human data.

Modeled as a dynamic web-based textbook, Anatomage eBook produces an interactive, aesthetically pleasing interface where students can explore a variety of anatomy and physiology topics using interactive controls. From tapping on the screen to scrolling the mouse, users are able to navigate through diverse anatomical parts. Adjacent and tiny structures are also highlighted with colors for distinguishment. Furthermore, cadaveric models can be rotated and engaged for a better view. Given its high interactivity, Anatomage eBook efficiently transforms the clinical and anatomical terminology into illustrative learning visuals that enhance students' memory.

Anatomage eBook is an effective learning tool for undergraduate Anatomy & Physiology students. To assist with assessing student learning, questions are included for various key topics in the textbook. Since Anatomage eBook can be accessed anywhere with Internet connectivity, it can be used as an online learning tool for both in-class and self-study sessions. By offering a multimedia platform combined with its accurate anatomy and physiology representation, Anatomage eBook embodies a new standard for digital textbooks in the medical education industry.

Adopting the Anatomage eBook will enable your students to -

For more information, please visit here or contact info@anatomage.com.

About AnatomageAs a market leader in medical virtualization technology, Anatomage enables an ecosystem of 3D anatomy hardware and software, allowing users to visualize anatomy at the highest level of accuracy. Established in both education and healthcare industries, Anatomage is transforming standard anatomy learning, medical diagnosis and treatment planning through its highly innovative products.Contact:Jack ChoiCEOAnatomage Inc.Phone: 1-408-885-1474Email: info@anatomage.comwww.anatomage.com

Read this article:
Anatomage Announces Its Upcoming eBook For Students To Experience and Interact with True-Human Cadavers Online - WFMZ Allentown

The psychology and physiology of pain management in athletics – AW – Athletics Weekly

Gateshead International Athletics Stadium, July 31, 1983

With just one week to go before the inaugural World Championships in Helsinki, some of the sports top names are fine-tuning their preparations before jetting off to Finland.

As a bridging distance between 800m and 1500m, the mens 1000m has attracted an international field of half milers and milers. As they take the bell in a respectable 1:26.58, a familiar face on the European circuit is leading in his distinctive white vest and matching wristbands.

Down the back straight for the last time and BBC Grandstand commentator David Coleman is waxing lyrical about the virtues of the elegant striding American out in front. This being said, the man who will go on to record a lifetime best of 1:44.62 over two laps in Stockholm a year later is most certainly a specialist half miler and the rolling of his head as the 800m point fast approaches, signals an impending changing of the guard.

At that moment, Moscow Olympic 800m champion Steve Ovett predictably devastatingly kicks and opens up a gap on the field with Don Paige giving dogged, if eventually futile, chase over the final 200 metres. An unflustered Ovett stops the clock at 2:19.06, saving his customary wave to the crowd until after the finishing line on this occasion.

Further down the field, the battle for the minor places continues as 1976 Olympic 1500m champion John Walker edges past the long-time race leader, whose shoulders have by now joined his head in rotational motion and who will eventually finish in fifth place.

Thirty-seven years later, laughing as he recalls his capitulation over the final furlong, James Mays jokes: I was left looking like the coyote in an episode of Wile E. Coyote and the Road Runner! His lay citation to matters of the zoological continue as comparisons to a North American species of canine are soon superseded by reference to a mammal namely monkeys.

The man who achieved international recognition for his pacemaking work in the 1980s, which famously included guiding Steve Cram to a world mile record in Oslo in the summer of 1985, recalls: When I was running at Texas Tech, my team-mates coined the phrase Monkey City. I thought it was funny and a great description of how a runner feels when theyre in the final push of a race.

The thought of monkeys riding your back with the sound of eek, eek in your ear was quite amusing!

In his moment of jest, the three-time All American collegiate champion may well be speaking words of truth and offering us a few hidden gems in terms of both the psychology and physiology of pain management among athletes.

The sensation of pain occurs as a result of brain neuronal activity in the encephalon. The experience of pain is of course unpleasant but a necessity when one considers its vitality as a signalling function which enables us to ultimately avoid death and maintain homeostasis in biological terms.

The functionality of pain is that it serves as an adaptive function, allowing us as athletes to know when we have encountered our optimal load, be it in the realms of running, jumping or throwing. In disaggregating the notion of pain, Domzal (1996) spoke about three facets in terms of the somatic (sensual feeling), the cognitive (psychological) and emotional (which is the value judgement we place on pain). This is compatible with the work of Azevedo and Samulski (2003), who noted that while athletes seem to have pain thresholds similar to non-athletes, critically their tolerance to pain may well be higher. So in essence, its not what we experience biologically, but how we perceive that experience psychologically.

Pain is subjective and relative which is why the man who now teaches both at school and university level in his native Dallas continues: Of course there are times when you dont feel like youre attacked by monkeys, but actual gorillas!

What Mays might be referring to would be classified by the likes of Haythornwaite et al (1998) as a specific form of coping strategy for pain management. Rather than ignoring Monkey City, Mays recollections of that Gateshead race challenge us as to whether we should adopt a strategy of Mindfulness based upon acceptance that as endurance-based athletes, at some point in our races we will inevitably feel as if we live in such a frightening urban metropolis. This again has some support from the sports psychology literature in that Salwin and Zajac (2016) perceptively point out: Knowing when to expect the difficulties makes it easier for the competitor to prepare and overcome them This means that an athlete can, to a certain degree, prepare for pain.

So rather than running away from pain, we should actually be prepared to hug and embrace it.

While psychologically it clearly helped an athlete like Mays to objectify and externalise his pain as a monkey, references to Monkey City were shared among his collegiate athlete community. This means they must be understood at the sociological level because shared humour is subcultural and its learned behaviour.

This is no surprise in that pain is central to our sport. The ability to joke about pain is functional for us athletes and there is of course a plethora of literature around how humour can keep us well both psychologically and biologically (See Hassed, 2001). Humour is a necessity, not during a race but certainly when embarking upon the slog of training its a defence mechanism against quitting.

While psychologically accepting that one will encounter pain, elite level performers like Mays will always attempt to develop physiological strategies to try and deal with the build-up of acid in their blood which is one of the biological drivers of the psychological experience of inhabiting Monkey City.

In recent years, the esteemed Oregon-based coach Peter Thompson (see http://www.newintervaltraining.com) has done much good work to further the understanding of what exercise physiologists would term acidosis. When lactic acid is formed it dissociates into lactate and acid, the latter of which is formed of hydrogen ions. At the point at which the production of hydrogen ion exceeds the bodys ability to buffer and clear because the kidneys and lungs cant keep the systems pH in balance, acidosis is said to occur and thus athletes enter the gateways of Monkey City.

At the appropriate point of the periodisation cycle, intense training simply has to be performed in order to both physically and psychologically prepare both body and mind to cope with the accumulation of high amounts of hydrogen ions, which may be perceived as Monkey City in experiential terms.

In previous decades, coach education discourses have incorrectly termed this as lactate tolerance training. The aforementioned Thompson perceptively points out that a more useful term is in fact acidosis tolerance training because lactate itself can be functional for the body.

So how did Mays prepare in terms of the specificity of his own acidosis tolerance training for his visit to Monkey City?

The workout that I did which best prepared me to negotiate Monkey City was a 600m speed endurance, he says. I would run to the 600m mark and then jog 150m through the curve, turn around and jog back to the 200m start. At that point I would blast the final 200m.

I would do three sets of those and at the end I was totally exhausted but it simulated in the 800m and I felt it prepared me to compete at a higher level.

The work of the late national coach for middle-distance, Dave Sunderland (2005), would frame this as an event specific session. The three golden rules of this mode of session are (1) that each set always adds up to the target race distance; (2) that work is grouped into sets in order to allow sufficient recovery to undertaken work which challenges the lactate energy system; and (3) that second and/or third set repetition lengths tend to be shorter the than first set.

So it should be noted that Mays practice of this type of session included a differential element in terms of pacing namely that the 200m effort would be effected at a greater average pace than that over 600m. Additionally, unlike the doctrine offered by Sunderland (2005), he has undertaken sets of the same length of repetitions. So while Mays has deviated from a textbook way of undertaking event specific repetitions, he has done so in a way which serves his own individual developmental needs while remaining faithful to the underlying ethos or spirit of this mode of session.

So while Mays was a world-class 800m runner, lets take Sunderlands example of a world-class 1500m runner aiming to hypothetically run 3:30 first set = 500m (70s); 1 min recovery; 700m (98s); 30 sec recovery; 300m (42s) 15-20 min recovery. Second set = 5x300m (42s) 1 min recovery between repetitions.

The strengths of using the kind of event specific repetitions utilised by the man who was a regular for Team USA in the 1980s, along with the likes of Johnny Gray and Earl Jones, are that they are invaluable preparation for ones visit to Monkey City. The cautionary note is that this mode of session tends to be effected in the competition phase of the periodisation cycle only. This mode of session cannot be performed consistency over several months due to the considerable demands on the lactate energy system and excessive use will risk the kind of fatigue which can lead to both subsequent loss of form and potential injury.

The moral of the story is if you want to deal with the monkey on your back it is well worth having a natter to the man affectionately known as The Rabbit!

Questions for self-reflection

Matt Long is a former winner of the British Milers Club Horwill Award for Coach Education and the author of more than 250 coaching articles.He can be contacted at [emailprotected] for advice on this piece

For more on the latest athletics news, athletics events coverage and athletics updates, check out theAW homepageand our social media channels onTwitter,FacebookandInstagram

Follow this link:
The psychology and physiology of pain management in athletics - AW - Athletics Weekly